Podcast Archives - MPR

Podcast

MPR Weekly Dose Podcast 75

The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.

MPR Weekly Dose Podcast 74

Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.

MPR Weekly Dose Podcast 72

This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; Approval in acute bacterial skin and skin structure infections; And results from the tocilizumab-remdesivir combo trial.

MPR Weekly Dose Podcast 71

This week it’s all COVID related news; There’s new CDC guidance for those who are vaccinated; A first over-the-counter test that doesn’t require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there’s reports of vaccine local reactions.

MPR Weekly Dose Podcast 70

This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Use Authorization; There’s findings on the effectiveness of ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.

MPR Weekly Dose Podcast 69

An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.

MPR Weekly Dose Podcast Episode 66

On this week’s pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it’s development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID-19, respectively; And the FDA approve a new treatment for lupus nephritis.

MPR Weekly Dose Podcast Episode 65

On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.